Treace Medical Concepts (TMCI) Projected to Post Quarterly Earnings on Thursday

Treace Medical Concepts (NASDAQ:TMCI) is projected to issue its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $49.5970 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Treace Medical Concepts (NASDAQ:TMCI) last released its quarterly earnings results on Tuesday, January 9th. The company reported ($0.22) EPS for the quarter. The business had revenue of $33.06 million during the quarter. Treace Medical Concepts had a negative net margin of 23.01% and a negative return on equity of 46.76%. On average, analysts expect Treace Medical Concepts to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Treace Medical Concepts Stock Performance

Shares of TMCI opened at $6.55 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.52. The company has a market capitalization of $413.76 million, a price-to-earnings ratio of -8.29 and a beta of 0.69. The company’s 50 day simple moving average is $6.84 and its 200 day simple moving average is $6.43. Treace Medical Concepts has a 1 year low of $4.54 and a 1 year high of $10.79.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TMCI shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Treace Medical Concepts in a research report on Wednesday, October 8th. UBS Group reaffirmed a “neutral” rating and issued a $6.50 price target (down from $8.60) on shares of Treace Medical Concepts in a research note on Friday, August 8th. Stifel Nicolaus reduced their price target on shares of Treace Medical Concepts from $9.00 to $6.00 and set a “hold” rating for the company in a research note on Friday, August 8th. Finally, Truist Financial dropped their target price on shares of Treace Medical Concepts from $8.00 to $7.00 and set a “hold” rating on the stock in a report on Wednesday, October 15th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.67.

Institutional Investors Weigh In On Treace Medical Concepts

Several large investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. grew its holdings in Treace Medical Concepts by 328.3% during the 2nd quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock valued at $28,000 after buying an additional 3,674 shares in the last quarter. Captrust Financial Advisors purchased a new stake in Treace Medical Concepts in the second quarter worth approximately $62,000. Invesco Ltd. lifted its position in Treace Medical Concepts by 18.6% in the second quarter. Invesco Ltd. now owns 15,051 shares of the company’s stock valued at $88,000 after purchasing an additional 2,362 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Treace Medical Concepts during the second quarter valued at approximately $102,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Treace Medical Concepts by 133,241.9% during the second quarter. Russell Investments Group Ltd. now owns 41,336 shares of the company’s stock valued at $243,000 after acquiring an additional 41,305 shares in the last quarter. Hedge funds and other institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.